Inspire Medical Systems (NYSE:INSP) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Inspire Medical Systems (NYSE:INSP) from a strong sell rating to a hold rating in a research report report published on Monday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the stock. Freedom Capital upgraded shares of Inspire Medical Systems to a “strong-buy” rating in a research note on Tuesday, June 30th. Piper Sandler cut shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $85.00 to $55.00 in a research note on Tuesday, May 5th. Bank of America downgraded shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price objective on the stock. in a research report on Friday, May 22nd. Oppenheimer restated a “market perform” rating on shares of Inspire Medical Systems in a research note on Monday, June 15th. Finally, Summit Redstone set a $39.00 target price on shares of Inspire Medical Systems in a report on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $81.05.

Inspire Medical Systems Price Performance

Shares of Inspire Medical Systems stock opened at $50.14 on Monday. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03. The company’s fifty day simple moving average is $44.31 and its 200-day simple moving average is $61.08. The stock has a market capitalization of $1.44 billion, a PE ratio of 11.17, a P/E/G ratio of 5.01 and a beta of 0.71.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The company had revenue of $204.58 million for the quarter, compared to analysts’ expectations of $200.04 million. During the same period last year, the firm earned $0.10 EPS. Inspire Medical Systems’s revenue for the quarter was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, research analysts anticipate that Inspire Medical Systems will post 0.93 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Wellington Management Group LLP bought a new stake in shares of Inspire Medical Systems during the 4th quarter worth approximately $203,929,000. Wasatch Advisors LP increased its position in shares of Inspire Medical Systems by 7.2% during the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after acquiring an additional 110,288 shares during the period. Morgan Stanley raised its stake in shares of Inspire Medical Systems by 179.5% during the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after acquiring an additional 809,121 shares in the last quarter. Deerfield Management Company L.P. boosted its holdings in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares during the period. Finally, State Street Corp boosted its holdings in shares of Inspire Medical Systems by 2.3% in the second quarter. State Street Corp now owns 1,030,902 shares of the company’s stock valued at $133,780,000 after purchasing an additional 22,843 shares during the period. Institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.